Who are Phio Pharmaceuticals Corp.'s main suppliers?

Phio Pharmaceuticals Corp. (PHIO) key suppliers include: AGONOX, H-C-WAINWRIGHT-CO-LLC, U-S-MANUFACTURER, TRITON-FUNDS-LP, ADVANCED-RNA-TECHNOLOGIES-LLC. View the full supplier network at chainsifter.com/chain/PHIO.

What sector is Phio Pharmaceuticals Corp. in?

Phio Pharmaceuticals Corp. (PHIO) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Phio Pharmaceuticals Corp. Suppliers, Customers & Supply Chain (PHIO)

5Suppliers

0Customers

2Debt Items

0Related Chains

Source-Backed Evidence Depth

Phio Pharmaceuticals Corp. (PHIO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

8Total relationships

5Distinct source URLs

8High confidence

0.901Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Phio Pharmaceuticals Corp. Suppliers

Ticker	Name	Confidence	Evidence
AGONOX	AGONOX	92%	Per the terms of the Clinical Co-Development Agreement, the Company agreed to reimburse AgonOx up to $ 4,000,000 in expenses incurred to conduct a Phase 1 clinical trial of PH- 762 treated DP TIL in …
H-C-WAINWRIGHT-CO-LLC	H-C-WAINWRIGHT-CO-LLC	92%	On April 8, 2026, Phio Pharmaceuticals Corp. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (the “Sales Agent…
U-S-MANUFACTURER	U-S-MANUFACTURER	92%	Phio Pharmaceuticals Corp. has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply.
TRITON-FUNDS-LP	TRITON-FUNDS-LP	90%	the Company agreed to sell, and Triton agreed to purchase, upon the Company’s request in one or more transactions, up to 862,500 shares of Common Stock
ADVANCED-RNA-TECHNOLOGIES-LLC	ADVANCED-RNA-TECHNOLOGIES-LLC	85%	Advirna assigned to the Company its existing patent and technology rights related to the INTASYL technology in exchange for an annual maintenance fee of $ 100,000

Phio Pharmaceuticals Corp. Customers

No clients on recordPhio Pharmaceuticals Corp. does not appear to disclose named customer relationships in its verified regulatory filings. Many companies do not publicly name customers in regulatory disclosures.

Phio Pharmaceuticals Corp. Debt Obligations

Instrument	Description	Confidence	Evidence
PHIO-DEBT-11769	Warrants outstanding: 2.86	90%	xbrl warrant detail from xbrl 2026-03-31.
PHIO-DEBT-11770	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.

Phio Pharmaceuticals Corp. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Phio Pharmaceuticals Corp..

Phio Pharmaceuticals Corp. Ownership

Holder	Name	Confidence	Evidence
PHIO-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 25 tracked holders.

Phio Pharmaceuticals Corp. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.

Phio Pharmaceuticals Corp. Supply Chain